S513
Clinical - Haemotology
ESTRO 2026
during follow- up.
department. Mean age was 70 years (range, 41-85). Stage I disease was the most frequent presentation. All patients received definitive RT; one also received rituximab. Radiotherapy was delivered using a linear accelerator (AGILITY) with 6 MV photons using Intensity-Modulated Radiotherapy (IMRT) with VMAT technique and image-guided radiotherapy (IGRT). Treatment response, relapse, survival and adverse events (graded per CTCAE v5.0) were collected from clinical records. QoL were assessed in 18p using the EORTC QLQ-C30 and QLQ-STO22 questionnaires. Descriptive statistics were used for demographic and clinical variables. Local control and survival were analyzed with the Kaplan–Meier method by SPSS.
Conclusion: Definitive RT for gastric MALT lymphoma provides excellent local control, minimal adverse events, and preservation of QoL. These results support RT as a highly effective, well-tolerated, and organ-sparing treatment in localized gastric MALT lymphoma. References: 1. Reduced-dose Radiation Therapy for Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Multi-Institutional Prospective Study (KROG 16-18). Jeon SH et al. Int J Radiat Oncol Biol Phys. 2025;121(4):1000–1005.2. Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. Yahalom J et al. Int J Radiat Oncol Biol Phys. 2015;92(1):11–31. 3. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines. Zucca E, Dreyling M; ESMO Guidelines Working Group. Ann Oncol. 2010;21 Suppl 5:v175–v176. Keywords: Lymphoma, Quality of life, Clinical outcomes Proffered Paper 3190 Outcome after low- vs. high-dose whole brain radiotherapy +/- boost in primary CNS lymphoma – results from a comparative multicenter analysis Sina Heider 1,2 , Jan C Bigge 3 , Luisa Allwohn 4 , Alexander Rühle 1,2 , Felix Ehret 4,5 , David Kaul 4,6 , Manuel Guhlich 3 , Stefan Rieken 3 , Michael Oertel 7 , Niklas B Pepper 8 , Elgin Hoffmann 9 , Raphael Bodensohn 7 , Arne Ruder 10 , Ilinca Popp 11 , Roland Merten 12 , Hans T Eich 8 , Denise Bernhardt 13 , Folker Schneller 14 , Elisabeth Schorb 15 , Nanna Wielenberg 11 , Stephanie E. Combs 16 , Anca L. Grosu 11 , Nils H Nicolay 1,2 , Clemens Seidel 1,2
Results: At a median follow-up of 26.4 months, overall survival was 94.7%, with one patient dying without disease recurrence. No local relapses occurred resulting in a 100% local control rate. The mean time to complete response was 4.1 months (median 3.5; range, 1.7– 10.4). Acute adverse events were observed in 12p (63.2%), with only one grade ≥ 3 event (diarrhea due to Clostridium difficile infection). The most frequent grade 1–2 adverse events were nausea (31.6%), dyspepsia (31.6%), diarrhea (21.1%), anorexia (21.1%), and dysphagia (10.5%). QoL questionnaires were available for 18p. Global health and functional scales in QLQ-C30 showed preserved QoL, with all domain scores above 90%, reflecting excellent functional status. Symptom scores were low (<15%), with the highest being pain (13.89%), insomnia (11.11%) and constipation (11.11%). According to the QLQ-STO22, patients reported very low symptom burden, with only mild dry mouth (11.11%) and occasional pain (9.26%), indicating minimal treatment-related gastrointestinal adverse events. In the QLQ-C30, higher scores in functional and global scales indicate better QoL, whereas higher symptom scores in both QLQ-C30 and QLQ-STO22 reflect greater symptom burden. No significant QoL deterioration was observed
Made with FlippingBook - Share PDF online